Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Related MRK
Merck Has An Upcoming PDUFA Date For Bezlotoxumab
Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
Here's How Lilly And Merck Are Faring In The Cancer Drug Wars: Earnings Out Next Week (Seeking Alpha)
Related GE
The Market In 5 Minutes: Big Earnings In Focus And A Tobacco Giant In The Making
GE's Q3 Results Show Double-Digit Bottom-Line Growth
Week In Review: Netflix And Pizza, Microsoft's Cloud Lofty As eBay, Intel Guide Low (Investor's Business Daily)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News


Related Articles (GE + MRK)

View Comments and Join the Discussion!